Dyne Therapeutics’ (DYN) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note published on Friday,Benzinga reports. The firm currently has a $50.00 target price on the stock.

A number of other analysts have also recently weighed in on DYN. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Royal Bank of Canada initiated coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Stock Down 31.1 %

Shares of NASDAQ DYN opened at $15.87 on Friday. The stock’s 50 day moving average price is $27.29 and its two-hundred day moving average price is $34.15. Dyne Therapeutics has a 52-week low of $14.79 and a 52-week high of $47.45. The stock has a market capitalization of $1.62 billion, a P/E ratio of -4.46 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Dirk Kersten sold 23,671 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the stock. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the period. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares during the period. State Street Corp boosted its position in shares of Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares during the period. RTW Investments LP boosted its position in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the period. Finally, RA Capital Management L.P. boosted its position in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after buying an additional 331,940 shares during the period. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.